Panitumumab (Vectibix)

Policy ID: I-117-009

Section: Injections

Effective Date: February 01, 2020

Revised Date: October 30, 2023

Revision Effective Date: January 01, 2024

Last Reviewed: November 15, 2023

Applies To: Commercial and Medicaid Expansion

Description

Panitumumab (Vectibix®) is a human, IgG2 kappa recombinant, monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). It is an injectable drug that may be used in the treatment of colorectal cancer.

Criteria

Coverage is subject to the specific terms of the member's benefit plan.

Federal Employee Program members (FEP) should check with their Retail Pharmacy Program to determine if prior approval is required by calling the Retail Pharmacy Program at 1-800-624-5060 (TTY: 1-800-624-5077). FEP members can also obtain the list through the www.fepblue.org website.

Panitumumab ( Vectibix) may be considered medically necessary for the treatment of metastatic colorectal cancer (mCRC) when the following are met:

Individuals with wild-type RAS (defined as wild-type in both KRAS and NRAS) mCRC as determined by an FDA-approved test as ANY of the following:
- First-line therapy in conjunction with FOLFOX (fluorouracil, leucovorin, and oxaliplatin); or
- Monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy; or

Compendia Sources

Panitumumab (Vectibix) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.

The use of panitumumab (Vectibix) for all other indications not listed in this policy is considered experimental/investigational and therefore non-covered because the safety and/or effectiveness cannot be established by the available published peer-reviewed literature.

Procedure Code

J9303

NOTE: In addition to the above criteria, product specific dosage and/or frequency limits may apply in accordance with the United States Food and Drug Administration (U.S. FDA)-approved product prescribing information, national compendia, Centers for Medicare and Medicaid Services (CMS) and other peer reviewed resources or evidence-based guidelines.

Diagnosis Codes

C18.0

C18.2

C18.3

C18.4

C18.5

C18.6

C18.7

C18.8

C18.9

C19

C20

C21.8

C78.00

C78.01

C78.02

C78.6

C78.7

Professional Statements and Societal Positions Guidelines

Not Applicable

ND Committee Review

Internal Medical Policy Committee 1-22-2020 New Policy

Internal Medical Policy Committee 1-19-2021 Annual review, no clinical content change

Internal Medical Policy Committee 7-22-2021 Updated NCCN recommendations and diagnosis codes

Internal Medical Policy Committee 7-21-2022 Annual review, no clinical content change

Internal Medical Policy Committee 11-29-2022

Removed NCCN recommendations; and
Added this statement 'Panitumumab (Vectibix) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.'; and
Updated experimental/investigational statement; and
Removed diagnosis codes C17.0, C17.1, C17.2, C17.8, C17.9, Z85.038 and Z85.068

Internal Medical Policy Committee 11-15-2023 Effective January 01, 2024

Removed diagnosis code C18.1

Links

References (PDF)

Disclaimer

Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.

Policy ID: I-117-008

Section: Injections

Effective Date: February 01, 2020

Revised Date: November 08, 2022

Revision Effective Date: January 01, 2023

Last Reviewed: November 29, 2022

Archived Date: December 31, 2023

Applies To: Commercial and Medicaid Expansion

Description

Criteria

Coverage is subject to the specific terms of the member’s benefit plan.

Panitumumab (Vectibix) may be considered medically necessary for the treatment of metastatic colorectal cancer (mCRC) when the following are met:

Individuals with wild-type RAS (defined as wild-type in both KRAS and NRAS) mCRC as determined by an FDA-approved test as ANY of the following:
- First-line therapy in conjunction with FOLFOX (fluorouracil, leucovorin, and oxaliplatin); or
- Monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy; or

Compendia Sources

Panitumumab (Vectibix) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.

Procedure Codes

J9303

NOTE: In addition to the above criteria, product specific dosage and/or frequency limits may apply in accordance with the U.S. Food and Drug Administration (FDA)-approved product prescribing information, national compendia, Centers for Medicare and Medicaid Services (CMS) and other peer reviewed resources or evidence-based guidelines.

Diagnosis Codes

C18.0

C18.1

C18.2

C18.3

C18.4

C18.5

C18.6

C18.7

C18.8

C18.9

C19

C20

C21.8

C78.00

C78.01

C78.02

C78.6

C78.7

Professional Statements and Societal Positions Guidelines

Not Applicable

ND Committee Review

Internal Medical Policy Committee 1-22-2020 New Policy

Internal Medical Policy Committee 1-19-2021 Annual review, no clinical content change

Internal Medical Policy Committee 7-22-2021 Updated NCCN recommendations and diagnosis codes

Internal Medical Policy Committee 7-21-2022 Annual review, no clinical content change

Internal Medical Policy Committee 11-29-2022

Removed NCCN recommendations; and
Added this statement "Panitumumab (Vectibix) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations."; and
Updated experimental/investigational statement; and
Removed diagnosis codes C17.0, C17.1, C17.2, C17.8, C17.9, Z85.038 and Z85.068

Links

References (PDF)

Disclaimer

Our Partners in Health:
Members
Employers
Producers

Fargo (Headquarters)
4510 13th Ave. S.
Fargo, N.D., 58121

Medical Policies Quick Search